These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 18711344)
1. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. O'Connor LM; Langabeer S; McCann SR; Conneally E Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344 [No Abstract] [Full Text] [Related]
2. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250 [TBL] [Abstract][Full Text] [Related]
3. Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain. Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Cupri A; Consoli C; Messina L; Tirrò E; Messina A; Di Raimondo F Leuk Res; 2009 Sep; 33(9):e157-8. PubMed ID: 19406471 [No Abstract] [Full Text] [Related]
4. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation. Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151 [TBL] [Abstract][Full Text] [Related]
5. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation. Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210 [No Abstract] [Full Text] [Related]
7. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Radich J Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552 [TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. Gopcsa L; Barta A; Bányai A; Dolgos J; Halm G; Pálóczi K Pathol Oncol Res; 2003; 9(2):131-3. PubMed ID: 12858220 [TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma. Mughal TI; Goldman JM Eur J Cancer; 2001 Mar; 37(5):561-8. PubMed ID: 11290430 [No Abstract] [Full Text] [Related]
10. Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. Hayat A; McCann SR; Langabeer S; Irvine S; McMullin MF; Conneally E Haematologica; 2009 Feb; 94(2):296-8. PubMed ID: 19109219 [No Abstract] [Full Text] [Related]
11. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408 [TBL] [Abstract][Full Text] [Related]
13. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Zeidan A; Kakati S; Anderson B; Barcos M; Wetzler M Cancer Genet Cytogenet; 2007 Jul; 176(2):169-71. PubMed ID: 17656263 [No Abstract] [Full Text] [Related]
14. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251 [TBL] [Abstract][Full Text] [Related]
16. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889 [TBL] [Abstract][Full Text] [Related]
18. After imatinib: new hopes for chronic myeloid leukaemia. Bradbury J Drug Discov Today; 2005 Apr; 10(8):536-7. PubMed ID: 15837592 [No Abstract] [Full Text] [Related]
19. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747 [TBL] [Abstract][Full Text] [Related]
20. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Bacigalupo A Leukemia; 2003 Sep; 17(9):1722. PubMed ID: 12970770 [No Abstract] [Full Text] [Related] [Next] [New Search]